A LONG-TERM FOCUS
            ON INNOVATION

            We welcome the opportunity to discuss:

            BUSINESS
            DEVELOPMENT
            COLLABORATIONS

            • In-licensing and / or R&D collaborations
              • Creative collaborations in emerging fields
              • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
            • Strategic late-stage development and commercial partnerships with other leading biopharma companies
            • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

            Introduce your assets or discuss
            late-stage partnership

            ACADEMIC &
            RESEARCH
            COLLABORATIONS

            • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

            Learn more

            • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

            Learn more

            OUR BUSINESS DEVELOPMENT STRATEGY

            Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

            We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

            • Novel platforms that enable next-generation therapeutics
            • Technologies for antibody discovery and development against new / challenging targets
            • New approaches that enhance activity of tumor-directed antibodies
            • Biomarker discovery and validation
            • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
            • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
            • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

            SOME OF OUR CURRENT COLLABORATORS INCLUDE:


            BAYER logo

            Global ophthalmology
            collaborations

            SANOFI logo

            Antibody and immunotherapy
            collaborations

            Icahn School of Medicine at Mount Sinai logo

            Antibody discovery
            agreement

            Columbia University logo

            Research collaboration on genetic
            basis of familial disease

            TEVA logo

            Global collaboration for
            investigational pain therapeutic

            Intellia Therapeutics logo

            Gene-editing technology
            collaboration

            Adicet Bio logo

            Engineered immune cell
            therapeutics collaboration

            Alnylam Pharmaceuticals logo

            RNA interference (RNAi)
            therapeutics collaboration

            色老大欧美大炮香蕉在线播放